(PR-inside.com) - ImClone Systems Incorporated Tracy Henrikson, 908-243-9945 Corporate Communications or Rebecca Gregory, 646-638-5058 Corporate Communications media@imclone.com ImClone Systems Incorporated (NASDAQ: IMCL) today announced the commercial launch of ERBITUX(R) (cetuximab) in Canada for use in the treatment of metastatic colorectal cancer (mCRC). Bristol-Myers Squibb collaborates with ImClone on ERBITUX in North America and is making the product commercially available through its wholly-owned subsidiary Bristol-Myers Squibb Canada. ERBITUX is approved by Health Canada for use in combination with irinotecan in the treatment of patients with epidermal growth factor receptor (EGFR)-expressing mCRC who are refractory to other irinotecan-based chemotherapy, and as single ..
More...
More...